Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients. Zadik Y. Oral Oncol. 2018 Sep. doi: 10.1016/j.oraloncology.2018.07.016. [Epub 2018 Jul 29.] Proteasome inhibitors for multiple myeloma. Okazuka K and Ishida T. Jpn J Clin Oncol. 2018 Sep 1. doi: 10.1093/jjco/hyy108. The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.…
Early salivary changes in multiple myeloma patients undergoing autologous HSCT.
van Leeuwen S et al. Oral Dis. 2018 Sep. doi: 10.1111/odi.12866
Vos JM et al. J Neurol Neurosurg Psychiatry. 2018 Sep. doi: 10.1136/jnnp-2017-316689.
miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1. Jian CM et al. Pathol Res Pract. 2018 Sep. doi: 10.1016/j.prp.2018.07.025. [Epub 2018 Jul 27] Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation‑dependent apoptosis. Zeng C et al. Oncol Rep. 2018 Sep. doi: 10.3892/or.2018.6544.…
Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. Sivik JM et al. Support Care Cancer. 2018 Mar 21. doi: 10.1007/s00520-018-4165-6. [Epub ahead of print]. Evaluation of the relevance of surgery in patients with multiple myeloma harboring symptomatic spinal involvement: a retrospective case series. Quidet M et al. World Neurosurg. 2018 Mar 9. pii: S1878-8750(18)30458-3. doi: 10.1016/j.wneu.2018.02.184.…
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Katodritou E et al. Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6. Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome. Ganzel C et…
The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study. Oortgiesen BE et al. Haematologica. 2018 Mar 15. pii: haematol.2017.184754. doi: 10.3324/haematol.2017.184754. [Epub ahead of print]. Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT. Pan Q et al. Clin Nucl Med. 2018 Mar 13. doi: 10.1097/RLU.0000000000002067. [Epub ahead of…
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Cho H et al. Invest New Drugs. 2018 Mar 9. doi: 10.1007/s10637-018-0582-0. [Epub ahead of print].
Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. Marinac CR et al. Br J Cancer. 2018 Mar 12. doi: 10.1038/s41416-018-0010-4. [Epub ahead of print]. Multidrug resistance 1 (MDR1/ABCB1) gene polymorphism (rs1045642 C > T) and susceptibility to multiple myeloma: a systematic review and meta-analysis. Razi B et al. Hematology. 2018 Mar 1:1-7. doi: 10.1080/10245332.2018.1443897.…
Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Augeul-Meunier K et al. Bone Marrow Transplant. 2018 Mar 9. doi: 10.1038/s41409-018-0122-8. [Epub ahead of print]. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation…
Calcified Alveolar Septal Pulmonary Amyloidosis as an Initial Manifestation of Multiple Myeloma. Kevorkof GV et al. Arch Bronconeumol. 2018 Mar 5. pii: S0300-2896(18)30020-6. doi: 10.1016/j.arbres.2018.01.005. [Epub ahead of print]. Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma. Bryant AR et al. Bone Marrow Transplant. 2018 Mar 7. doi: 10.1038/s41409-018-0142-4. [Epub ahead of print]. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management,…